drugset / Trial / NCT05274100
Study of Intravenous and Subcutaneous Administration of Risankizumab in Healthy Participants
RandomizedParallel-groupOpen-labelBasic science
Summary
The primary objectives of this study are to assess the relative bioavailability of risankizumab in on-body delivery system (OBDS) versus the prefilled syringe (PFS) (Substudy 1) and to assess the relative bioavailability of risankizumab in the to-be-marketed Dose A liquid vial versus the Dose B liquid vial used in the Phase 3 studies (Substudy 2).
Timeline
- Start
- 2020-09-01
- Primary completion
- 2021-07-06
- Completion
- 2021-07-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Risankizumab | Monoclonal antibody | — | Subcutaneous |
Indications
No indication recorded.